Literature DB >> 20206155

Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia.

J Schiettecatte1, H Russcher, E Anckaert, M Mees, B Leeser, A S Tirelli, G M Fiedler, H Luthe, B Denk, J Smitz.   

Abstract

OBJECTIVES: Performance evaluation of Elecsys sFlt-1 and PlGF assays. DESIGN AND METHODS: Within-, between-run, total imprecision, functional sensitivity, inter-laboratory comparison, method comparison and lot-to-lot reproducibility were evaluated.
RESULTS: Within- and between-run CVs were below 4% for sFlt-1 >60 and PlGF > 20 pg/mL. Total imprecision CVs were below 4.3%. Functional sensitivity was < 5 pg/mL. Inter-laboratory CVs were <5%. Elecsys correlated well with Quantikine VEGF-R1 (r=0.960) and PlGF (r=0.968). Lot-to-lot comparisons yielded highly correlated results (r>0.999). In healthy pregnancies, the median levels of sFlt-1 remained constant in first (1107 pg/mL) and second trimesters (1437 pg/mL) but increased in the third trimester (2395 pg/mL), while median PlGF levels increased in the first (30 pg/mL) and second trimesters (279 pg/mL) and peaked at 29 to 32 weeks (626 pg/mL) and decreased thereafter (340 pg/mL). The sFlt-1/PlGF ratio is highest in the first trimester (median: 28) but remained constant in the second (median: 4.7) and third trimesters (median: 5.1). In PE/HELPP samples matched for gestational age the sFlt-1 levels were significantly higher (6894-34,624 pg/mL), whereas PlGF levels were lower (9.2-80 pg/mL) and the median sFlt-1/PlGF ratio is much higher (461; range: 121-2614) than in apparently healthy pregnancies (3.6; range: 0.3-105).
CONCLUSION: The new Roche Elecsys sFlt-1 and PlGF immunoassay showed excellent precision and reliability. There was a clear difference in the Elecsys sFlt-1/PlGF ratio between samples obtained from women with apparently normal pregnancy at the time of blood collection and those diagnosed with PE/HELLP at the same age of gestation. 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206155     DOI: 10.1016/j.clinbiochem.2010.02.010

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  28 in total

Review 1.  Molecular Mechanisms of Preeclampsia.

Authors:  Tammy Hod; Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-20       Impact factor: 6.915

2.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

Review 3.  Anti-angiogenesis and Preeclampsia in 2016.

Authors:  Susanne Schrey-Petersen; Holger Stepan
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

Review 4.  Hypertensive disorders in pregnancy.

Authors:  Casey Berry; Mohamed G Atta
Journal:  World J Nephrol       Date:  2016-09-06

5.  Ratio between fms-like tyrosine kinase 1 and placental growth factor in children with congenital heart disease.

Authors:  Masaya Sugimoto; Hideharu Oka; Aya Kajihama; Kouichi Nakau; Seiko Kuwata; Clara Kurishima; Hiroshi Azuma
Journal:  Pediatr Cardiol       Date:  2014-11-12       Impact factor: 1.655

6.  Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice.

Authors:  Jacqueline G Parchem; Keizo Kanasaki; Megumi Kanasaki; Hikaru Sugimoto; Liang Xie; Yuki Hamano; Soo Bong Lee; Vincent H Gattone; Samuel Parry; Jerome F Strauss; Vesna D Garovic; Thomas F McElrath; Karen H Lu; Baha M Sibai; Valerie S LeBleu; Peter Carmeliet; Raghu Kalluri
Journal:  J Clin Invest       Date:  2018-10-08       Impact factor: 14.808

7.  The orphan nuclear receptor NUR77 promotes trophoblast invasion at early pregnancy through paracrine placental growth factor.

Authors:  Xiao-Cui Li; Xiang-Jie Yin; Wei Hong; Jie Liu; Feng Jin; Bei-Ying Wang; Yu-Mei Wang; Fu-Ju Tian
Journal:  J Mol Med (Berl)       Date:  2019-07-16       Impact factor: 4.599

8.  Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Josef M Cortez; Athina Pappas; Adi L Tarca; Piya Chaemsaithong; Zhong Dong; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2013-08-08

9.  2-methoxyestradiol plasma levels are associated with clinical severity indices and biomarkers of preeclampsia.

Authors:  Miriam Pertegal; Francisco J Fenoy; Barbara Bonacasa; Jaime Mendiola; Juan L Delgado; Moises Hernández; Miguel G Salom; Vicente Bosch; Isabel Hernández
Journal:  Reprod Sci       Date:  2014-06-04       Impact factor: 3.060

Review 10.  Pre-eclampsia: an update.

Authors:  Peter von Dadelszen; Laura A Magee
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.